University of Miami Hospital and Clinics / Sylvester Comprehensive Cancer Center
Welcome,         Profile    Billing    Logout  
 5 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Watts, Justin
NCT06311227: Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

Recruiting
2
20
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant
05/27
05/27
APTIVATE, NCT03850574: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
240
Europe, US, RoW
Tuspetinib, HM43239, Venetoclax Oral Tablet, Venetoclax, Azacitidine for Intravenous Infusion, Azacitidine
Aptose Biosciences Inc.
Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome with Excess Blasts-2, Chronic Myelomonocytic Leukemia
11/26
04/27
DSP-5336-101, NCT04988555: A Study of DSP-5336 in Relapsed/refractory AML/ ALL with or Without MLL Rearrangement or NPM1 Mutation

Recruiting
1/2
70
Europe, Canada, Japan, US, RoW
DSP-5336
Sumitomo Pharma America, Inc.
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
01/25
02/25
NCT04365179: Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML

Recruiting
1
18
US
Nerofe
Immune System Key Ltd, University of Miami Sylvester Comprehensive Cancer Center
Advanced MDS, AML
06/25
08/25
NCT06158100: Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

Recruiting
1
25
US
Venetoclax, Venclexta, Venclyxto, Azacitidine, Vidaza, Azadine, Donor Lymphocyte Infusion
Antonio M Jimenez Jimenez, AbbVie
Acute Myeloid Leukemia
12/26
12/27
POLARIS2020-002, NCT05001828: Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

Recruiting
1
60
US
ADI-PEG 20, Venetoclax, Azacitidine
Polaris Group
Acute Myeloid Leukemia, Adult
07/25
12/25
Chandhok, Namrata
NCI-2019-03057, NCT03953898: Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

Active, not recruiting
2
14
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
01/24
11/25
NCT05024994: A Study of E7820 in People With Bone Marrow (Myeloid) Cancers

Active, not recruiting
2
12
US
E7820
Memorial Sloan Kettering Cancer Center, Eisai Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
08/25
08/25
NCT06456463: A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

Recruiting
2
76
US, RoW
Tagraxofusp, Tag, Venetoclax, Ven, Azacitidine, Aza
Stemline Therapeutics, Inc.
Acute Myeloid Leukemia
02/28
02/30
NCT04365179: Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML

Recruiting
1
18
US
Nerofe
Immune System Key Ltd, University of Miami Sylvester Comprehensive Cancer Center
Advanced MDS, AML
06/25
08/25
NCT04477291: A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

Active, not recruiting
1
80
US
CG-806
Aptose Biosciences Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
12/24
05/25
SX682-MDS-102, NCT04245397: Study of SX-682 Alone and in Combination with Oral or Intravenous Decitabine in Subjects with Myelodysplastic Syndrome

Recruiting
1
151
US
SX-682, Decitabine, DEC-C
Syntrix Biosystems, Inc., H. Lee Moffitt Cancer Center and Research Institute, National Heart, Lung, and Blood Institute (NHLBI), AdventHealth, Emory University, University of Miami, Mayo Clinic, Montefiore Medical Center, National Cancer Institute (NCI), Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Myelodysplastic Syndromes
03/28
03/29
Bradley, Terrance
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Jan 2024 - Dec 2024: Approval for myelofibrosis
Hourglass Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Feb 2024 - Feb 2024: Exclusivity expiry in US
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
NCT04365179: Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML

Recruiting
1
18
US
Nerofe
Immune System Key Ltd, University of Miami Sylvester Comprehensive Cancer Center
Advanced MDS, AML
06/25
08/25

Download Options